Advertisement
MRK vs PFE
Which Stock Would AI Choose? Merck (MRK) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Merck and Pfizer are two of the largest U.S. pharmaceutical companies, but they are navigating markedly different post-pandemic trajectories in recent market activity.
- Merck has demonstrated stronger price momentum, with its stock up roughly 62% over the past year, fueled by oncology powerhouse KEYTRUDA and the rapid uptake of newer therapies such as WINREVAIR.
- Pfizer offers a considerably higher dividend yield — north of 6% — but faces a more immediate patent cliff between 2026 and 2030 and continued headwinds from declining COVID-19 product revenues.
- Both companies are actively reshaping their pipelines through acquisitions: Merck added Verona Pharma and Cidara Therapeutics, while Pfizer acquired Seagen, Metsera, and in-licensed obesity and oncology assets.
- Risk profiles diverge meaningfully — Merck's key vulnerability is concentration around KEYTRUDA, while Pfizer contends with a broader loss of exclusivity wave across multiple blockbuster drugs.
- For growth-oriented investors, Merck's execution and pipeline momentum may hold greater appeal; for income-focused investors, Pfizer's dividend yield and strategic turnaround potential warrant attention.
Introduction
Comparing MRK and PFE — two pharmaceutical giants with century-deep legacies — offers a compelling lens through which to examine contrasting approaches to pipeline development, portfolio diversification, and capital allocation. Both companies generate tens of billions in annual revenue, maintain expansive global footprints, and invest heavily in research and development (R&D). Yet their recent stock performance, growth trajectories, and market sentiment have diverged significantly. This stock comparison is particularly relevant for investors weighing quality pharma exposure: one company riding strong oncology-driven momentum, the other navigating a post-COVID normalization while pivoting toward high-growth therapeutic areas such as obesity. Understanding their relative positioning can help clarify where value and opportunity may currently reside.
MRK Overview and Recent Performance
MRK (Merck & Co., Inc.), headquartered in Rahway, New Jersey, operates across human pharmaceuticals, vaccines, and a sizable Animal Health division. Its portfolio is anchored by KEYTRUDA, the immuno-oncology drug that generated approximately $31.7 billion in full-year 2025 sales — accounting for nearly half of total pharmaceutical revenue and growing 7% year-over-year. In recent weeks, Merck's stock has traded near the upper end of its 52-week range, reflecting sustained investor confidence in the company's ability to expand KEYTRUDA into earlier-stage cancer indications while simultaneously launching next-generation growth drivers.
Among those new drivers, WINREVAIR — a treatment for pulmonary arterial hypertension (a rare condition affecting blood vessels in the lungs) — has delivered standout growth, with fourth-quarter 2025 sales surging 133% to $467 million. CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine, and WELIREG, a treatment for certain tumors associated with von Hippel-Lindau disease, have also contributed meaningfully. The company closed its acquisition of Verona Pharma in October 2025, adding OHTUVAYRE, a first-in-class inhaled therapy for chronic obstructive pulmonary disease (COPD), and later acquired Cidara Therapeutics to strengthen its antiviral pipeline. These moves reflect a deliberate strategy to diversify beyond oncology ahead of KEYTRUDA's anticipated patent expirations beginning in 2028. Full-year 2025 revenue reached $65.0 billion, with non-GAAP EPS of $8.98, up 17% from the prior year.
PFE Overview and Recent Performance
PFE (Pfizer Inc.), based in New York City, is one of the world's largest research-driven biopharmaceutical companies, with a portfolio spanning primary care, specialty care, and oncology. Following its dramatic revenue surge during the COVID-19 pandemic — driven by the Comirnaty vaccine and the antiviral Paxlovid — Pfizer has been navigating a pronounced revenue normalization. Full-year 2025 revenues came in at $62.6 billion, representing a 2% operational decline. Excluding COVID-19 products, however, operational revenue grew 6%, demonstrating underlying commercial strength.
In recent months, Pfizer has been repositioning aggressively for the future. The company closed its acquisition of Metsera, gaining a portfolio of ultra-long-acting GLP-1 receptor agonists (a class of drugs for obesity and diabetes that mimic a key metabolic hormone) aimed at the rapidly expanding obesity market. Positive phase IIb data for its lead obesity candidate, PF-08653944 (PF'3944), showed weight loss of up to 12.3% at 28 weeks with monthly dosing — a potential differentiator in a space dominated by weekly injectables. Pfizer also in-licensed a PD-1 x VEGF bispecific antibody from 3SBio, bolstering its oncology pipeline. Meanwhile, the company's non-COVID product portfolio — including Vyndaqel, Eliquis, Prevnar, and the Seagen-acquired oncology franchise — continues to generate steady or growing revenues. However, Pfizer faces a significant patent cliff from 2026 to 2030, with an expected $1.5 billion revenue headwind in 2026 alone from loss of exclusivity (LOE) across several key products. Full-year 2025 adjusted diluted EPS was $3.22.
Trending AI Robots
In an environment where pharmaceutical stocks are influenced by drug trial outcomes, regulatory decisions, patent timelines, and macroeconomic shifts, traders are increasingly turning to AI-driven tools to navigate complexity. Tickeron's Trending AI Robots page curates a selection of the platform's hundreds of AI trading bots — each designed to trade specific tickers using distinct strategies, timeframes, and technical indicators. Only the bots best aligned with prevailing market conditions earn placement in this featured section. These AI robots span a wide range of trading styles, from short-term swing trading to longer-duration trend-following approaches, and their performance statistics — including win rates, Sharpe ratios, and trade counts — are transparently displayed. Whether a trader is focused on large-cap pharma names like MRK and PFE or exploring opportunities across other sectors, browsing the Trending AI Robots can provide data-driven insights into which strategies are currently generating the most consistent signals.
Head-to-Head Comparison
The most striking contrast between Merck and Pfizer lies in their growth trajectories and market sentiment. Merck has delivered a roughly 62% total return over the past year, supported by consistent earnings beats and visible pipeline catalysts, while Pfizer's stock has struggled to regain investor enthusiasm despite beating earnings estimates for eight consecutive quarters. Merck benefits from a relatively concentrated but deeply entrenched oncology franchise; Pfizer's revenue base is broader but faces multiple simultaneous LOE events in the near term.
On pipeline strategy, both companies are active dealmakers, but their focus areas differ. Merck is layering cardiometabolic, respiratory, and antiviral assets around its oncology core. Pfizer is making a decisive push into obesity — a market projected to exceed $100 billion — while also reinforcing oncology through its Seagen acquisition. The risk-reward calculus differs: Merck's pipeline additions are nearer-term revenue contributors, while Pfizer's obesity bets could take years to fully materialize.
From a shareholder returns perspective, Pfizer's dividend yield of approximately 6.3% far exceeds Merck's roughly 2.7% yield, but Pfizer's elevated payout ratio (above 90%) raises questions about sustainability if earnings face further compression. Merck's lower yield is complemented by stronger price appreciation and a healthier payout ratio. In terms of risk factors, Merck's primary vulnerability is concentrated in KEYTRUDA's patent expiry timeline; Pfizer's risk is more distributed — spanning patent cliffs, COVID revenue erosion, and the execution uncertainty inherent in its strategic pivot toward obesity and next-generation oncology.
Tickeron AI Verdict
Based on observable trend consistency, relative momentum, and catalyst visibility, Tickeron's AI-driven analytical framework would likely favor MRK in the current market environment. Merck's stock has demonstrated stronger and more sustained upward momentum, supported by a combination of steady oncology cash flows and emerging growth from newer launches. Pfizer's strategic repositioning — particularly its obesity pipeline — holds long-term promise, but the nearer-term revenue headwinds from patent expirations and COVID normalization introduce greater uncertainty into the trend profile. That said, an AI-driven approach is inherently probabilistic and would continue to reassess both stocks as new data — earnings reports, trial results, and regulatory decisions — reshapes the landscape. The comparison is dynamic, and the relative attractiveness of each name can shift as market conditions evolve.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a StrongBuy and PFE is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRK’s FA Score shows that 2 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).
- MRK’s FA Score: 2 green, 3 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRK’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).
- MRK’s TA Score: 5 bullish, 4 bearish.
- PFE’s TA Score: 4 bullish, 5 bearish.
Price Growth
MRK (@Pharmaceuticals: Major) experienced а +2.80% price change this week, while PFE (@Pharmaceuticals: Major) price change was -0.32% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.95%. For the same industry, the average monthly price growth was +1.76%, and the average quarterly price growth was +4.67%.
Reported Earning Dates
MRK is expected to report earnings on Aug 04, 2026.
PFE is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.95% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| MRK | PFE | MRK / PFE | |
| Capitalization | 324B | 140B | 231% |
| EBITDA | 19.4B | 17.2B | 113% |
| Gain YTD | 26.345 | 3.641 | 724% |
| P/E Ratio | 36.92 | 18.73 | 197% |
| Revenue | 65.8B | 63.3B | 104% |
| Total Cash | N/A | N/A | - |
| Total Debt | 49.1B | 63.7B | 77% |
MRK | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 32 | 9 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 42 | 100 | |
SMR RATING 1..100 | 47 | 77 | |
PRICE GROWTH RATING 1..100 | 8 | 53 | |
P/E GROWTH RATING 1..100 | 7 | 46 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (3) in the Pharmaceuticals Major industry is significantly better than the same rating for MRK (87). This means that PFE’s stock grew significantly faster than MRK’s over the last 12 months.
MRK's Profit vs Risk Rating (42) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (100). This means that MRK’s stock grew somewhat faster than PFE’s over the last 12 months.
MRK's SMR Rating (47) in the Pharmaceuticals Major industry is in the same range as PFE (77). This means that MRK’s stock grew similarly to PFE’s over the last 12 months.
MRK's Price Growth Rating (8) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (53). This means that MRK’s stock grew somewhat faster than PFE’s over the last 12 months.
MRK's P/E Growth Rating (7) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (46). This means that MRK’s stock grew somewhat faster than PFE’s over the last 12 months.
| MRK | PFE | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 50% | 3 days ago 57% |
| Stochastic ODDS (%) | 3 days ago 52% | 3 days ago 56% |
| Momentum ODDS (%) | 3 days ago 59% | 3 days ago 47% |
| MACD ODDS (%) | 3 days ago 54% | 3 days ago 44% |
| TrendWeek ODDS (%) | 3 days ago 56% | 3 days ago 59% |
| TrendMonth ODDS (%) | 3 days ago 55% | 3 days ago 47% |
| Advances ODDS (%) | 3 days ago 55% | 11 days ago 54% |
| Declines ODDS (%) | 7 days ago 51% | 7 days ago 58% |
| BollingerBands ODDS (%) | 3 days ago 52% | 3 days ago 57% |
| Aroon ODDS (%) | 3 days ago 65% | 3 days ago 60% |
Advertisement
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with NVS. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then NVS could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.16% | ||
| BMY - PFE | 61% Loosely correlated | +0.94% | ||
| MRK - PFE | 55% Loosely correlated | +0.45% | ||
| AMGN - PFE | 53% Loosely correlated | +1.22% | ||
| NVS - PFE | 51% Loosely correlated | -0.72% | ||
| BIIB - PFE | 51% Loosely correlated | +0.78% | ||
More | ||||